Get the Stockscreener App
5.87
1.20%
0.06
Foghorn Therapeutics Inc stock is traded at $5.87, with a volume of 86,588.
It is up +1.20% in the last 24 hours and up +8.89% over the past month.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
See More
Previous Close:
$5.81
Open:
$5.78
24h Volume:
86,588
Relative Volume:
0.41
Market Cap:
$343.58M
Revenue:
$34.16M
Net Income/Loss:
$-98.43M
P/E Ratio:
-2.5085
EPS:
-2.34
Net Cash Flow:
$-119.33M
1W Performance:
+5.57%
1M Performance:
+8.89%
6M Performance:
-5.01%
1Y Performance:
+42.72%
1-Day Range:
$5.73
$5.95
1-Week Range:
$5.615
$6.285
52-Week Range:
$2.9448
$6.95
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Name
Foghorn Therapeutics Inc
Sector
Industry
Phone
617-586-3100
Address
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
5.865 | 340.36M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.94 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.19 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.84 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.23 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
335.08 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | BTIG Research | Buy |
| Nov-07-25 | Initiated | Guggenheim | Buy |
| Sep-17-25 | Resumed | B. Riley Securities | Buy |
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-30-25 | Initiated | B. Riley Securities | Buy |
| Sep-03-24 | Initiated | Jefferies | Buy |
| Aug-19-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-23 | Initiated | BofA Securities | Buy |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-22-21 | Initiated | H.C. Wainwright | Buy |
| Nov-17-20 | Initiated | Cowen | Outperform |
| Nov-17-20 | Initiated | Goldman | Buy |
| Nov-17-20 | Initiated | Morgan Stanley | Overweight |
| Nov-17-20 | Initiated | Wedbush | Outperform |
View All
Foghorn Therapeutics Inc Stock (FHTX) Latest News
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of “Buy” from Brokerages - Defense World
Foghorn Therapeutics Reports Q3 2025 Financial Results - MSN
Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics - Quantisnow
Foghorn Therapeutics (NASDAQ:FHTX) Shares Down 4.1%Time to Sell? - MarketBeat
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - Benzinga
Foghorn Therapeutics stock reaffirmed as Buy by BTIG, named top pick for 1H26 - Investing.com Canada
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium - GlobeNewswire
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 target - Investing.com Canada
Foghorn Therapeutics Announces $50 Million Equity Financing - TipRanks
Is Foghorn Therapeutics (NASDAQ:FHTX) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Insider Trends: Will Foghorn Therapeutics Inc stock benefit from green energy trendsJuly 2025 Review & Real-Time Stock Movement Alerts - Bộ Nội Vụ
What momentum indicators show for Foghorn Therapeutics Inc. stockJuly 2025 Catalysts & Safe Entry Trade Signal Reports - ulpravda.ru
Foghorn Therapeutics Inc. Secures $50 Million in Equity Financing to Advance Oncology Pipeline and Strengthen Balance Sheet | FHTX Stock News - Quiver Quantitative
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 - Yahoo Finance
Biotech raises $50M to push new lung and breast cancer drugs forward - Stock Titan
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic ... - Bluefield Daily Telegraph
Will Foghorn Therapeutics Inc. stock benefit from green energy trends - Улправда
Can Foghorn Therapeutics Inc. stock sustain free cash flow growthWeekly Investment Report & High Accuracy Trade Signal Alerts - Улправда
Can Foghorn Therapeutics Inc. stock reach $100 price targetEarnings Beat Highlights & Swing Trade Smarter With Data Insights - bollywoodhelpline.com
Why Foghorn Therapeutics Inc. stock is recommended by analystsRisk-Reward Ratio Analysis & Small Budget Big Profits - Улправда
Will Foghorn Therapeutics Inc. stock continue upward momentumBull Market Opportunities & Outstanding Wealth Building - ulpravda.ru
Is Foghorn Therapeutics Inc. stock a bargain at current levels2026 world cup usa national team group stage top scorers possession football odds analysis expert opinion - Улправда
Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX) and Foghorn Therapeutics (FHTX) - The Globe and Mail
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected - simplywall.st
Can Foghorn Therapeutics Stock Hold Up When Markets Turn? - Trefis
Is Foghorn Therapeutics Inc. stock resilient to inflation2025 Support & Resistance & Real-Time Chart Breakout Alerts - Улправда
BTIG Research Begins Coverage on Foghorn Therapeutics (NASDAQ:FHTX) - Defense World
Wall Street Zen Upgrades Foghorn Therapeutics (NASDAQ:FHTX) to "Buy" - MarketBeat
Is Foghorn Therapeutics Inc. stock supported by strong fundamentalsJuly 2025 Decliners & AI Forecast Swing Trade Picks - bolumsonucanavari.com
How Foghorn Therapeutics Inc. stock performs after earningsJuly 2025 Drop Watch & Reliable Breakout Stock Forecasts - Улправда
Foghorn Therapeutics (NASDAQ:FHTX) Earns Buy Rating from Analysts at BTIG Research - MarketBeat
Will Foghorn Therapeutics Inc. stock deliver better than expected guidanceWeekly Stock Recap & Proven Capital Preservation Tips - Улправда
Here's Why We're Watching Foghorn Therapeutics' (NASDAQ:FHTX) Cash Burn Situation - Sahm
BTIG Initiates Coverage of Foghorn Therapeutics (FHTX) with Buy Recommendation - Nasdaq
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment - Yahoo Finance
BTIG Research Initiates Coverage on Foghorn Therapeutics With Buy Rating, $11 Price Target - MarketScreener
BTIG Initiates Coverage on FHTX with a Buy Rating and $11.00 Pri - GuruFocus
Support Test: What momentum indicators show for Foghorn Therapeutics Inc. stockPortfolio Return Report & Low Risk Investment Opportunities - Улправда
BTIG initiates Foghorn Therapeutics stock with Buy rating on cancer pipeline - Investing.com Canada
Foghorn Therapeutics (NASDAQ:FHTX) vs. Arcadia Biosciences (NASDAQ:RKDA) Head to Head Analysis - Defense World
Estrella Immunopharma (NASDAQ:ESLA) & Foghorn Therapeutics (NASDAQ:FHTX) Head-To-Head Contrast - Defense World
Platform Technologies Drive $211B Surge in Precision Cancer Treatment - marketscreener.com
Analyst Confidence Rises for Foghorn Therapeutics Following Leadership and Pipeline Updates - AD HOC NEWS
Foghorn Therapeutics (NASDAQ:FHTX) Stock Rating Lowered by Wall Street Zen - Defense World
Is Foghorn Therapeutics Inc. stock attractive for hedge fundsJobs Report & AI Driven Stock Reports - Newser
Foghorn Therapeutics Appoints Interim CFO Jeff Sacher - The Globe and Mail
Stifel Initiates Coverage of Foghorn Therapeutics (FHTX) with Buy Recommendation - Nasdaq
Stifel Initiates Coverage on FHTX with a 'Buy' Rating | FHTX Sto - GuruFocus
Foghorn Therapeutics Inc appoints Jeff Sacher as interim CFO - marketscreener.com
Foghorn Therapeutics Inc Stock (FHTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):